Print

Fujifilm Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Novel Anti-Staph Biologic  
10/25/2011 9:15:59 AM

MORRISVILLE, N.C.--(BUSINESS WIRE)--Fujifilm Diosynth Biotechnologies and ContraFect Corporation announced today that they have signed a contract to support the process development and cGMP manufacture of CF-301, ContraFect’s Staphylococcal-specific bacteriophage lysin. CF-301 is ContraFect’s lead compound and displays potent activity against all forms of Staph infections, including methicillin-resistant (MRSA) and vancomycin-resistant strains (VISA/VRSA).
//-->